Research graph
References from A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor
10.1002/j.1460-2075.1995.tb00035.x · 1995 · External reference
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
10.1038/nri1901 · 2006 · External reference
The role of interleukin-2 during homeostasis and activation of the immune system
10.1038/nri3156 · 2012 · External reference
Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15
10.1016/s1074-7613(00)80564-6 · 1998 · External reference
Cytokines in clinical cancer immunotherapy
10.1038/s41416-018-0328-y · 2019 · External reference
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
10.1002/cncr.23552 · 2008 · External reference
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
10.1186/s40425-017-0279-5 · 2017 · External reference
IL-2: the first effective immunotherapy for human cancer
10.4049/jimmunol.1490019 · 2014 · External reference
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
10.1182/blood-2010-03-275438 · 2010 · External reference
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer
10.1200/jco.2014.57.3329 · 2015 · External reference
A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors
10.1158/1078-0432.ccr-17-2451 · 2018 · External reference
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
10.1136/jitc-2020-002193 · 2021 · External reference
IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion
10.1158/1078-0432.ccr-18-3468 · 2019 · External reference
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
10.1073/pnas.1811615115 · 2018 · External reference
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
10.18632/oncotarget.20680 · 2017 · External reference
Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
10.1182/bloodadvances.2021006440 · 2023 · External reference
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma
10.1080/10428194.2024.2326847 · 2024 · External reference
Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine
10.1093/intimm/11.1.81 · 1999 · External reference
The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma
10.1158/1078-0432.ccr-04-0983 · 2004 · External reference
Increased CCR4 expression in cutaneous T cell lymphoma
10.1046/j.1523-1747.2002.19610.x · 2002 · External reference
Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells
10.1182/blood.v99.5.1505 · 2002 · External reference
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma
10.1200/jco.2013.52.0924 · 2014 · External reference
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
10.1182/blood-2014-09-600924 · 2015 · External reference
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
10.1016/s1470-2045(18)30379-6 · 2018 · External reference
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
10.3324/haematol.2016.146977 · 2016 · External reference
Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
10.3324/haematol.2018.205096 · 2019 · External reference
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
10.1182/bloodadvances.2020003053 · 2020 · External reference
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma [abstract]
10.1200/jco.2023.41.16_suppl.7504 · 2023 · External reference
Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
10.1182/blood.2021013341 · 2022 · External reference
Revised adult T-cell leukemia-lymphoma International Consensus Meeting Report
10.1200/jco.18.00501 · 2019 · External reference
The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee
10.1182/blood.2022015851 · 2022 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
10.3389/fimmu.2015.00368 · 2015 · External reference
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
10.3324/haematol.2017.186577 · 2018 · External reference
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
10.1111/bjh.14477 · 2017 · External reference
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
10.1182/bloodadvances.2021005899 · 2022 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
10.1056/nejmoa011795 · 2002 · External reference
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
10.1200/jco.20.03175 · 2021 · External reference
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies
10.1158/1078-0432.ccr-08-1254 · 2009 · External reference
REDIRECT: a phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL) [abstract]
2023 · External reference
CAR-T cell therapy: current limitations and potential strategies
10.1038/s41408-021-00459-7 · 2021 · External reference
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
10.1182/blood.2023022204 · 2024 · External reference
10.1182/blood-2018-99-110429
10.1182/blood-2018-99-110429 · 2018 · External reference
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
10.1200/jco.2002.20.1.205 · 2002 · External reference
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
10.1080/10428194.2017.1387908 · 2018 · External reference
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
10.1038/s41375-020-0838-5 · 2021 · External reference
Anti-tumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
10.1182/blood.2023022204 · 2024 · External reference
Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
10.1182/blood.2021015020 · 2022 · External reference
First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed/refractory TRBC1-positive peripheral T-cell lymphoma
10.1182/blood-2022-165971 · 2022 · External reference
CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma
10.1182/blood-2022-160244 · 2022 · External reference
The cobalt-LYM study of CTX130: a phase 1 dose escalation study of CD70 targeted allogeneic CRISPR-CAS9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies [abstract]
10.1097/01.hs9.0000843940.96598.e2 · 2022 · External reference
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
10.1016/s0140-6736(18)32984-2 · 2019 · External reference
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
10.1182/bloodadvances.2021004710 · 2021 · External reference
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
10.1200/jco.2011.38.0402 · 2012 · External reference
Innate cell engager (ICE®) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: final results [abstract]
10.1182/blood-2023-172980 · 2023 · External reference
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
10.1038/s41586-024-07233-2 · 2024 · External reference
Evidence for NK cell subsets based on chemokine receptor expression
10.4049/jimmunol.177.11.7833 · 2006 · External reference
CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy
10.1182/bloodadvances.2023012202 · 2024 · External reference
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
10.1056/nejmoa1910607 · 2020 · External reference
Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma
10.1158/1078-0432.ccr-20-4575 · 2021 · External reference
Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus calmette-guérin (BCG) for the treatment of bladder cancer
10.1080/2162402x.2021.1912885 · 2021 · External reference
